The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are phthalazine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X.sub.3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).

The present invention relates to compounds of formula (I) inhibiting P2X purinoceptor 3; particularly the invention relates to compounds that are phthalazine derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X.sub.3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).

The invention provides a polymerizable compound of formula (I), polymerizable composition, polymer, and optically anisotropic article capable of obtaining an optical film having a low melting point, excellent solubility, being manufactured at low cost, and of uniform polarized light conversion across a broad wavelength region. In formula (I): Y.sup.1 to Y.sup.6 are independently a chemical single bond, O, OC(O), C(O)O; G.sup.1 and G.sup.2 are independently a divalent C1-C20 aliphatic group; Z.sup.1 and Z.sup.2 are independently a C2-C10 alkenyl group substituted with a halogen atom; A.sup.x is a C2-C30 organic group that includes at least one aromatic ring of an aromatic hydrocarbon ring or an aromatic hetero ring; A.sup.y is H, a C1-C20 alkyl group, a C2-C20 alkenyl group, a C3-C12 cycloalkyl group; A.sup.1 is a trivalent aromatic group; A.sup.2 and A.sup.3 are independently a divalent C6-C30 aromatic group; and Q.sup.1 is H, or a C1-C6 alkyl group. ##STR00001##

The invention provides a polymerizable compound of formula (I), polymerizable composition, polymer, and optically anisotropic article capable of obtaining an optical film having a low melting point, excellent solubility, being manufactured at low cost, and of uniform polarized light conversion across a broad wavelength region. In formula (I): Y.sup.1 to Y.sup.6 are independently a chemical single bond, O, OC(O), C(O)O; G.sup.1 and G.sup.2 are independently a divalent C1-C20 aliphatic group; Z.sup.1 and Z.sup.2 are independently a C2-C10 alkenyl group substituted with a halogen atom; A.sup.x is a C2-C30 organic group that includes at least one aromatic ring of an aromatic hydrocarbon ring or an aromatic hetero ring; A.sup.y is H, a C1-C20 alkyl group, a C2-C20 alkenyl group, a C3-C12 cycloalkyl group; A.sup.1 is a trivalent aromatic group; A.sup.2 and A.sup.3 are independently a divalent C6-C30 aromatic group; and Q.sup.1 is H, or a C1-C6 alkyl group. ##STR00001##

Provided herein are methods of using KRAS G12C inhibitors and compositions of the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Provided herein are methods of using KRAS G12C inhibitors and compositions of the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.

Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.